# Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

> **NCT02622113** · PHASE4 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 139 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Canagliflozin (TA-7284)
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT02622113
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02622113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02622113, "Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02622113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*